Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? (original) (raw)

Journal Article

,

Regenerative Medicine Institute (REMEDI) College of Medicine, Nursing and Health Sciences, National University of Ireland

, Galway,

Ireland

Correspondence: Prof. Matthew D. Griffin, MB BCh, DMed, REMEDI, NCBES, Orbsen Building, National University of Ireland, Galway; Galway, Ireland. Telephone: +353-91-495436; Fax: +353-91-495547; e-mail: matthew.griffin@nuigalway.ie

Search for other works by this author on:

,

Orbsen Therapeutics Ltd.

, University Road, Galway,

Ireland

Search for other works by this author on:

,

Institute of Immunology National University of Ireland, Maynooth, Co.

, Kildare,

Ireland

Search for other works by this author on:

,

Institute of Immunology National University of Ireland, Maynooth, Co.

, Kildare,

Ireland

Search for other works by this author on:

,

Regenerative Medicine Institute (REMEDI) College of Medicine, Nursing and Health Sciences, National University of Ireland

, Galway,

Ireland

Search for other works by this author on:

Regenerative Medicine Institute (REMEDI) College of Medicine, Nursing and Health Sciences, National University of Ireland

, Galway,

Ireland

Search for other works by this author on:

Revision received:

15 May 2013

Published:

28 October 2013

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Matthew D. Griffin, Stephen J. Elliman, Emer Cahill, Karen English, Rhodri Ceredig, Thomas Ritter, Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?, Stem Cells, Volume 31, Issue 10, October 2013, Pages 2033–2041, https://doi.org/10.1002/stem.1452
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

Mesenchymal stromal (stem) cells (MSCs) continue to be a strong area of focus for academic- and industry-based researchers who share the goal of expanding their therapeutic use for diverse inflammatory and immune-mediated diseases. Recently, there has been an accelerated rate of scientific publication, clinical trial activity, and commercialisation in the field. This has included the reporting of exciting new developments in four areas that will be of key importance to future successful use of MSC-based therapies in large numbers of patients: (a) fundamental biology of the primary cells in bone marrow and other tissues that give rise to MSCs in culture. (b) Mechanisms by which MSCs modulate immune and inflammatory responses in vivo. (c) Insights into MSC kinetics, safety, and efficacy in relevant animal disease models. (d) Isolation, definition, and clinical trial-based testing of human MSCs by biomedical companies and academic medical centers. Despite this progress, it remains unclear whether MSCs will enter mainstream therapeutic practice as a frequently used alternative to pharmacotherapy or surgical/radiological procedures in the foreseeable future. In this review, we summarize some of the most significant new developments for each of the four areas that contribute to the process of translating MSC research to the clinical arena. In the context of this recent progress, we discuss key challenges and specific knowledge gaps which, if not addressed in a coordinated fashion, may hinder the creation of robust “translational pipelines” for consolidating the status of MSC-based therapies.

© AlphaMed Press

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model)

You do not currently have access to this article.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? - 24 Hours access

EUR €51.00

GBP £44.00

USD $55.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 605

418 Pageviews

187 PDF Downloads

Since 1/1/2022

Citations

113 Web of Science

×

Email alerts

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic